Clinical Trials Browser

Active not recruiting × Has results × Ganglioneuroblastoma × Clear all

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Phase 2 Active not recruiting

41 enrolled 13 charts

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2025-10-09

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 2 Active not recruiting

42 enrolled 12 charts

Ganglioneuroblastoma